• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Quest Diagnostics (NY: DGX )

    156.97 +0.74 (+0.47%)
    Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 883,729
    Open 155.92
    Bid (Size) 156.26 (1)
    Ask (Size) 157.54 (1)
    Prev. Close 156.23
    Today's Range 155.49 - 157.34
    52wk Range 119.59 - 157.34
    Shares Outstanding 122,180,759
    Dividend Yield 1.81%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What Analysts Are Saying About Quest Diagnostics Stock
    Via Benzinga
    Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
    Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
    Via Benzinga

    Performance

    YTD
    +11.47%
    +11.47%
    1 Month
    +10.31%
    +10.31%
    3 Month
    +10.57%
    +10.57%
    6 Month
    +25.90%
    +25.90%
    1 Year
    +19.37%
    +19.37%

    More News

    Read More
    8 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
    Via Benzinga
    Uncovering Dividend Opportunities with NYSE:DGX.
    Via Chartmill
    5 Analysts Assess Quest Diagnostics: What You Need To Know
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
    Via Benzinga
    How Is The Market Feeling About Quest Diagnostics?
    Via Benzinga
    Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
    Via Benzinga
    Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
    Via Benzinga
    DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Peering Into Quest Diagnostics's Recent Short Interest
    Via Benzinga
    Analyst Scoreboard: 7 Ratings For Quest Diagnostics
    Via Benzinga
    How Is The Market Feeling About Quest Diagnostics?
    Via Benzinga
    US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
    From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
    Via GlobeNewswire
    Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Peering Into Quest Diagnostics's Recent Short Interest
    Via Benzinga
    Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
    Via Benzinga
    EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
    Via Benzinga
    S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
    Via MarketBeat
    Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
    Via AB Newswire
    Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.